Advertisement

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study

Published:August 19, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.07.021

      Highlights

      • Chemotherapy dose modification is common in ovarian cancer treatment.
      • Patients requiring dose modification are more likely to require growth factor.
      • Dose modified patients are at a higher risk of worse treatment outcome.

      Abstract

      Purpose

      To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin and paclitaxel.

      Methods

      Women with stages III and IV EOC and PPC treated on the Gynecologic Oncology Group phase III trial, protocol 182, who completed eight cycles of carboplatin with paclitaxel were evaluated in this study. The patients were grouped per dose modification and use of granulocyte colony stimulating factor (G-CSF). The primary end point was OS; Hazard ratios (HR) for PFS and OS were calculated for patients who completed eight cycles of chemotherapy. Patients without dose modification were the referent group. All statistical analyses were performed using the R programming language and environment.

      Results

      A total of 738 patients were included in this study; 229 (31%) required dose modification, 509 did not. The two groups were well-balanced for demographic and prognostic factors. The adjusted hazard ratios (HR) for disease progression and death among dose-modified patients were: 1.43 (95% CI, 1.19–1.72, P < 0.001) and 1.26 (95% CI, 1.04–1.54, P = 0.021), respectively. Use of G-CSF was more frequent in dose-modified patients with an odds ratio (OR) of 3.63 (95% CI: 2.51–5.26, P < 0.001) compared to dose-unmodified patients.

      Conclusion

      Dose-modified patients were at a higher risk of disease progression and death. The need for chemotherapy dose modification may identify patients at greater risk for adverse outcomes in advanced stage EOC and PPC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Parkin D.M.
        • Bray F.
        • Ferlay J.
        • Pisani P.
        Global cancer statistics, 2002.
        CA Cancer J. Clin. 2005; 55: 74-108
        • American Cancer Society
        Cancer Facts & Figures 2011.
        American Cancer Society, Atlanta2011
        • Vergote I.
        • Trope C.G.
        • Amant F.
        • Kristensen G.B.
        • Ehlen T.
        • Johnson N.
        • et al.
        Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
        N. Engl. J. Med. 2010; 363: 943-953
        • Jemal A.
        • Siegel R.
        • Ward E.
        • Hao Y.
        • Xu J.
        • Thun M.J.
        Cancer statistics, 2009.
        CA Cancer J. Clin. 2009; 59: 225-249
        • Bolis G.
        • Scarfone G.
        • Polverino G.
        • Raspagliesi F.
        • Tateo S.
        • Richiardi G.
        • et al.
        Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
        J. Clin. Oncol. 2004; 22: 686-690
        • Watring W.
        • Semrad N.
        • Alaverdian V.
        • Latino F.
        • Pretorius G.
        Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982–1985.
        Gynecol. Oncol. 1989; 32: 245-247
        • Hakes T.B.
        • Chalas E.
        • Hoskins W.J.
        • Jones W.B.
        • Markman M.
        • Rubin S.C.
        • et al.
        Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
        Gynecol. Oncol. 1992; 45: 284-289
        • Bertelsen K.
        • Jakobsen A.
        • Stroyer J.
        • Nielsen K.
        • Sandberg E.
        • Andersen J.E.
        • et al.
        A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
        Gynecol. Oncol. 1993; 49: 30-36
        • Lambert H.E.
        • Rustin G.J.
        • Gregory W.M.
        • Nelstrop A.E.
        A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group study.
        Ann. Oncol. 1997; 8: 327-333
        • Wood W.C.
        • Budman D.R.
        • Korzun A.H.
        • Cooper M.R.
        • Younger J.
        • Hart R.D.
        • et al.
        Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
        N. Engl. J. Med. 1994; 330: 1253-1259
        • Colleoni M.
        • Price K.
        • Castiglione-Gertsch M.
        • Goldhirsch A.
        • Coates A.
        • Lindtner J.
        • et al.
        Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
        Eur. J. Cancer. 1998; 34: 1693-1700
        • Chirivella I.
        • Bermejo B.
        • Insa A.
        • Perez-Fidalgo A.
        • Magro A.
        • Rosello S.
        • et al.
        Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
        Breast Cancer Res. Treat. 2009; 114: 479-484
        • Bookman M.A.
        • Brady M.F.
        • McGuire W.P.
        • Harper P.G.
        • Alberts D.S.
        • Friedlander M.
        • et al.
        Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
        J. Clin. Oncol. 2009; 27: 1419-1425
        • Epelbaum R.
        • Faraggi D.
        • Ben-Arie Y.
        • Ben-Shahar M.
        • Haim N.
        • Ron Y.
        • et al.
        Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables.
        Cancer. 1990; 66: 1124-1129
        • Thatcher N.
        • Girling D.J.
        • Hopwood P.
        • Sambrook R.J.
        • Qian W.
        • Stephens R.J.
        Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
        J. Clin. Oncol. 2000; 18: 395-404
        • Siegel R.
        • Ward E.
        • Brawley O.
        • Jemal A.
        Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
        CA Cancer J. Clin. 2011; 61: 212-236
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • Trimble E.L.
        • Montz F.J.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
        J. Clin. Oncol. 2002; 20: 1248-1259
        • Aabo K.
        • Adams M.
        • Adnitt P.
        • Alberts D.S.
        • Athanazziou A.
        • Barley V.
        • et al.
        Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
        Br. J. Cancer. 1998; 78: 1479-1487
      1. BMJ. 1991; 303 (No authors listed): 884-893
      2. J. Clin. Oncol. 1991; 9 (No authors listed): 1668-1674
        • A'Hern R.P.
        • Gore M.E.
        Impact of doxorubicin on survival in advanced ovarian cancer.
        J. Clin. Oncol. 1995; 13: 726-732
        • McGuire W.P.
        • Hoskins W.J.
        • Brady M.F.
        • Kucera P.R.
        • Partridge E.E.
        • Look K.Y.
        • et al.
        Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
        N. Engl. J. Med. 1996; 334: 1-6
        • Piccart M.J.
        • Bertelsen K.
        • James K.
        • Cassidy J.
        • Mangioni C.
        • Simonsen E.
        • et al.
        Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
        J. Natl. Cancer Inst. 2000; 92: 699-708
        • Muggia F.M.
        • Braly P.S.
        • Brady M.F.
        • Sutton G.
        • Niemann T.H.
        • Lentz S.L.
        • et al.
        Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2000; 18: 106-115
        • Ozols R.F.
        • Bundy B.N.
        • Greer B.E.
        • Fowler J.M.
        • Clarke-Pearson D.
        • Burger R.A.
        • et al.
        Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2003; 21: 3194-3200
        • du Bois A.
        • Luck H.J.
        • Meier W.
        • Adams H.P.
        • Möbus V.
        • Costa S.
        • et al.
        A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
        J. Natl. Cancer Inst. 2003; 95: 1320-1329
        • Neijt J.P.
        • Engelholm S.A.
        • Tuxen M.K.
        • Sorensen P.G.
        • Hansen M.
        • Sessa C.
        • et al.
        Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
        J. Clin. Oncol. 2000; 18: 3084-3092
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • Huang H.Q.
        • Baergen R.
        • Lele S.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354: 34-43
        • Cannistra S.A.
        Cancer of the ovary.
        N. Engl. J. Med. 2004; 351: 2519-2529
        • Petignat P.
        • Fioretta G.
        • Verkooijen H.M.
        • Vlastos A.T.
        • Rapiti E.
        • Bouchardy C.
        • et al.
        Poorer survival of elderly patients with ovarian cancer: a population-based study.
        Surg. Oncol. 2004; 13: 181-186

      Linked Article